Lisata Therapeutics, Inc.
LSTA•NASDAQ•Healthcare•Biotechnology

About Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Company Information

SectorHealthcare
IndustryBiotechnology
CEODavid Mazzo
Founded1980
Employees26
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.lisata.com
Phone908 842 0100
Address
110 Allen Road, 2nd Floor Basking Ridge, New Jersey 07920 United States

Corporate Identifiers

CIK0000320017
CUSIP128058302
ISINUS1280583022
EIN22-2343568
SIC2834

Leadership Team & Key Executives

Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.
President, Chief Executive Officer and Director
James Nisco
Senior Vice President of Finance, Treasurer, CAO and Principal Financial and Accounting Officer
Dr. Kristen K. Buck M.D.
Executive Vice President of Research & Development and Chief Medical Officer
Tariq Imam
Senior Vice President of Business Development and Operations and General Counsel
Gregory S. Berkin
Chief Information and Data Protection Officer
John D. Menditto
Vice President of Investor Relations and Corporate Communications
Dr. William K. Sietsema Ph.D.
Vice President of Global Regulatory Affairs